Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

Association between type 1 diabetes mellitus and epilepsy: more than coincidence?

Authors: Tiago Silva Aguiar, Joana Rodrigues Dantas Vezzani, Débora Batista de Araújo, Soniza Vieira Alves-Leon, Lenita Zajdenverg, Melanie Rodacki, Marco Antônio Salles Dantas de Lima

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

Type 1 diabetes mellitus (T1D) patients have an increased risk of seizures at extremes of glycemic control. There is growing evidence about the role of autoimmunity in the epileptogenesis and glutamic acid decarboxylase antibodies (GAD-ab), a well known antibody related to neurologic diseases, can be a link that justifies epilepsy in T1D population. GAD catalyzes the conversion of glutamic acid, the main excitatory central nervous system (CNS) amino acid, into gamma-aminobutyric acid (GABA), the main inhibitory CNS neurotransmitter. GABA-secreting neurons and pancreatic beta cells are the major cells expressing GAD. Seizures may be result of imbalance between excitation and inhibition determined by inhibition of GAD activity caused by autoantibodies. The potential pathogenic role of GAD-ab in neurological disorders is not fully understood, but inhibition of GABA synthesis or interfering with the exocytosis are plausible hypotheses. The spectrum of neurological disorders associated with GAD-ab includes cerebellar ataxia, myoclonus palatal, limbic encephalitis, encephalomyelitis, stiff person syndrome and others. …
Metadata
Title
Association between type 1 diabetes mellitus and epilepsy: more than coincidence?
Authors
Tiago Silva Aguiar
Joana Rodrigues Dantas Vezzani
Débora Batista de Araújo
Soniza Vieira Alves-Leon
Lenita Zajdenverg
Melanie Rodacki
Marco Antônio Salles Dantas de Lima
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A210

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine